Cargando…
Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world
BACKGROUND: Prescribing patterns for stroke prevention in atrial fibrillation (AF) patients evolved with approval of non‐Vitamin K antagonist oral anticoagulants (NOACs) over time. OBJECTIVES: To assess changes in anticoagulant prescription patterns in various geographical regions upon first approva...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339088/ https://www.ncbi.nlm.nih.gov/pubmed/34386125 http://dx.doi.org/10.1002/joa3.12588 |
_version_ | 1783733521690394624 |
---|---|
author | Kozieł, Monika Teutsch, Christine Bayer, Valentina Lu, Shihai Gurusamy, Venkatesh K. Halperin, Jonathan L. Rothman, Kenneth J. Diener, Hans‐Christoph Ma, Chang‐Sheng Huisman, Menno V. Lip, Gregory Y. H. |
author_facet | Kozieł, Monika Teutsch, Christine Bayer, Valentina Lu, Shihai Gurusamy, Venkatesh K. Halperin, Jonathan L. Rothman, Kenneth J. Diener, Hans‐Christoph Ma, Chang‐Sheng Huisman, Menno V. Lip, Gregory Y. H. |
author_sort | Kozieł, Monika |
collection | PubMed |
description | BACKGROUND: Prescribing patterns for stroke prevention in atrial fibrillation (AF) patients evolved with approval of non‐Vitamin K antagonist oral anticoagulants (NOACs) over time. OBJECTIVES: To assess changes in anticoagulant prescription patterns in various geographical regions upon first approval of a NOAC and to analyze the evolution of oral anticoagulants (OACs) use over time in relation to CHA(2)DS(2)‐VASc and HAS‐BLED risk profiles. METHODS: Global Registry on Long‐Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA‐AF) Phases II and III reported data on antithrombotic therapy for patients with newly diagnosed AF and ≥1 stroke risk factor. We focused on sites enrolling patients in both phases and reported treatment patterns for the first 4 years after initial NOAC approval. RESULTS: From GLORIA‐AF Phases II and III, 27 432 patients were eligible for this analysis. When contrasting the first year with the fourth year of enrolment, the proportion of NOAC prescriptions increased in Asia from 29.2% to 60.8%, in Europe from 53.4% to 75.8%, in North America from 49.0% to 73.9% and in Latin America from 55.7% to 71.1%. The proportion of Vitamin K antagonists (VKAs) use decreased across all regions over time, in Asia from 26.0% to 9.8%, in Europe from 35.5% to 16.8%, in North America from 28.9% to 12.1%, and in Latin America from 32.4% to 17.8%. In the multivariable analysis, factors associated with NOAC prescription were as follows: enrolment year, type of site, region, stroke and bleeding risk scores, and type and categorization of AF. CONCLUSIONS: During 4 years after the approval of the first NOAC, NOAC use increased, while VKA use decreased, across all regions. |
format | Online Article Text |
id | pubmed-8339088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83390882021-08-11 Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world Kozieł, Monika Teutsch, Christine Bayer, Valentina Lu, Shihai Gurusamy, Venkatesh K. Halperin, Jonathan L. Rothman, Kenneth J. Diener, Hans‐Christoph Ma, Chang‐Sheng Huisman, Menno V. Lip, Gregory Y. H. J Arrhythm Original Articles BACKGROUND: Prescribing patterns for stroke prevention in atrial fibrillation (AF) patients evolved with approval of non‐Vitamin K antagonist oral anticoagulants (NOACs) over time. OBJECTIVES: To assess changes in anticoagulant prescription patterns in various geographical regions upon first approval of a NOAC and to analyze the evolution of oral anticoagulants (OACs) use over time in relation to CHA(2)DS(2)‐VASc and HAS‐BLED risk profiles. METHODS: Global Registry on Long‐Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA‐AF) Phases II and III reported data on antithrombotic therapy for patients with newly diagnosed AF and ≥1 stroke risk factor. We focused on sites enrolling patients in both phases and reported treatment patterns for the first 4 years after initial NOAC approval. RESULTS: From GLORIA‐AF Phases II and III, 27 432 patients were eligible for this analysis. When contrasting the first year with the fourth year of enrolment, the proportion of NOAC prescriptions increased in Asia from 29.2% to 60.8%, in Europe from 53.4% to 75.8%, in North America from 49.0% to 73.9% and in Latin America from 55.7% to 71.1%. The proportion of Vitamin K antagonists (VKAs) use decreased across all regions over time, in Asia from 26.0% to 9.8%, in Europe from 35.5% to 16.8%, in North America from 28.9% to 12.1%, and in Latin America from 32.4% to 17.8%. In the multivariable analysis, factors associated with NOAC prescription were as follows: enrolment year, type of site, region, stroke and bleeding risk scores, and type and categorization of AF. CONCLUSIONS: During 4 years after the approval of the first NOAC, NOAC use increased, while VKA use decreased, across all regions. John Wiley and Sons Inc. 2021-07-10 /pmc/articles/PMC8339088/ /pubmed/34386125 http://dx.doi.org/10.1002/joa3.12588 Text en © 2021 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of Japanese Heart Rhythm Society https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Kozieł, Monika Teutsch, Christine Bayer, Valentina Lu, Shihai Gurusamy, Venkatesh K. Halperin, Jonathan L. Rothman, Kenneth J. Diener, Hans‐Christoph Ma, Chang‐Sheng Huisman, Menno V. Lip, Gregory Y. H. Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world |
title | Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world |
title_full | Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world |
title_fullStr | Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world |
title_full_unstemmed | Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world |
title_short | Changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world |
title_sort | changes in anticoagulant prescription patterns over time for patients with atrial fibrillation around the world |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339088/ https://www.ncbi.nlm.nih.gov/pubmed/34386125 http://dx.doi.org/10.1002/joa3.12588 |
work_keys_str_mv | AT koziełmonika changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT teutschchristine changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT bayervalentina changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT lushihai changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT gurusamyvenkateshk changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT halperinjonathanl changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT rothmankennethj changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT dienerhanschristoph changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT machangsheng changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT huismanmennov changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT lipgregoryyh changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld AT changesinanticoagulantprescriptionpatternsovertimeforpatientswithatrialfibrillationaroundtheworld |